Limited Time Offer
Get $1000 towards your
first investment
Start investing in private markets with Linqto – your access to disruptive startups and pre-IPO companies.
*Terms and conditions apply. See details
Bioage, founded in 2001 and headquartered in Sao Paulo, Brazil, is a company specializing in the development and marketing of dermo-cosmetics in the Brazilian market. The company has established itself as a player in the skincare industry, focusing on innovative cosmetic products.
On July 8th, 2021, Bioage was acquired by Hypera Pharma, a significant development in the company's history. The terms of this acquisition were not publicly disclosed, leaving investors curious about the potential impact on Bioage's future operations and market position.
Given the recent acquisition by Hypera Pharma, there is currently no public information available regarding Bioage's IPO prospects. The company's future plans, including any potential public offering, remain undisclosed at this time. As such, investors interested in Bioage stock or looking to buy Bioage shares should be aware that the company is not currently publicly traded.
It's important to note that the lack of information about Bioage's IPO plans is not unusual, especially following an acquisition. The company's future direction and any decisions regarding going public will likely be influenced by its new parent company, Hypera Pharma. Investors keen on following Bioage's progress should monitor official announcements from the company or Hypera Pharma for any updates on potential investment opportunities.
Get $1000 towards your
first investment
*Terms and conditions apply. See details
While BioAge's IPO prospects remain uncertain, investors interested in the longevity and biotechnology sectors don't have to wait on the sidelines. At Linqto, we offer members the opportunity to invest in promising private companies before they go public. Our platform provides access to a diverse range of pre-IPO investments, including potential leaders in the biotech industry like BioAge, with lower minimum investments than traditional private equity opportunities. This allows you to potentially benefit from the growth of innovative companies addressing age-related diseases and expanding healthspan.
*These comments should not be interpreted to mean that the company is formally pursuing or foregoing an IPO. The information provided above is based on current online discussions and is not intended as investment advice. Linqto does not endorse or guarantee the accuracy of this information, and we strongly recommend conducting your own research or consulting with a professional advisor before making any investment decisions. Linqto cannot be held liable for any investment outcomes resulting from the use of this information.
